company profile

AMI Technologies ltd - is a leading distributor of medical devices and innovative technology in Israel.
The company was established by Rami Dulberg in 1986, Rami is biomedical engineer that has been working in the medical industry for over 30 years and gained vast experience and knowledge.
Our mission is to contribute to the advancement of healthcare in Israel, by introducing use of novel, Added value, state of the art medical technology products.
We implement an intensive search and development process in order to identify breakthrough medical devices that address unmet clinical needs.
Our company is committed to marketing successfully in its territory innovative, cost-effective products in high growth market segments, to investing the resources required to develop new product concepts and to ensuring a leadership position in the emerging medical technology segment.
We adhere to the highest professional and ethical standards towards all our customers, our employees and our partners. We are also strongly committed to contributing in the community, in which we live and work.
AMI Technologies ltd - enjoys a leadership position in all the core medical products in the market. The company has been awarded a number of times by its global partners. This outstanding market performance is based on the company's clear and focused business strategy, the diversity and uniqueness of its product portfolio, as well as the professional competence and scientific approach shared by its people. The company is looking forward to further expanding into marketing partnership agreements with promising medical device companies offering breakthrough technology and innovative products

204 Second Ave., Waltham, MA 02451
o-781-902-1625, c-508-944-8015

Augmenix is focused on improving the outcomes of radiotherapy through the use of absorbable hydrogels. The company is using this technology to develop products that decrease unintended radiation damage to normal organs. SpaceOAR System reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate. TraceIT Tissue Marker is an injectable hydrogel that is visible under CT, cone beam, ultrasound and MR imaging and has found good utility in bladder marking. Following radiation the hydrogel gradually liquefies and is absorbed and cleared from the body.

Breslauer LTD
58B Amal Street
POB 10082
Petach Tikvah
ISRAEL 4900102

Tel: +972-3-9187000
Fax: +972-3-9222646
Email –
Established in 1939, Breslauer LTD is a leading value added distributor that provides a wide range of solutions for hospitals and clinics. In the urology field, Breslauer LTD exclusively represents several of the renowned global companies, including the following:
KARL STORS - Endo-Urology, Laparoscopic Surgeries, OR1.
STORZ MEDICAL - Shockwave Lithotripsy, Shockwave Therapy.
STERIS - Sterile Reprocessing Equipment, OR Table and Light.
MMS - Urodynamics and Anorectal Manometry.
ROCAMED – Endo- Urology Fluid Management (ENDOFLOW), Disposables for Endo-Urology.
MEDIFA – Urology Examination Chairs.


Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes ostomy care, urology and continence care, and wound and skin care. We operate globally, employing more than 10,000 people.
Closeness to all customers makes this possible. We listen to better understand needs, and respond by finding new ways to do things better together. We lead the way by bringing the best ideas first and fast to market in the form of medical devices and service solutions.

Direx Group, established over 30 years ago, has continuously extended its presence in countries and markets worldwide. The Group utilizes unique breakthrough technologies and the products are characterized by reliability, modularity and transportability-combined with cost effectiveness and ease of use. More than a thousand systems, predominantly in Urology have been placed in over 70 countries. Product lines include Shock Wave Lithotripsy (including dual-head and portable stationary patient systems), Thermal Therapy, Radiotherapy, Laser and ED treatment with the first dedicated shockwave system for Erectile Dysfunction treatment (focusing the energy on a line-segment). Worldwide network of committed service centers assure adequate support and maintenance.

Dover Medical & Scientific Equipment Ltd.
11 Hamaalot St., Herzliya 46583
Tel. 972-(0)9-9514545
Fax 972-(0)9-9580151

Dover Medical & Scientific Equipment, Ltd., founded in 1974, is one of the leading companies in the Israeli medical market, incorporating revolutionary and high technologies. Our clients include: Ministry of Health Hospitals, University Hospitals, Private Hospitals, Clinics and Research Institutes.
Dover focuses on medical and diagnostic solutions.
Our medical division covers such fields as Surgery, ICU, Urology, Gynecology, and IT and hospital logistics.
Our diagnostic division covers Lab Automation, Blood Banking, Hematology, Clinical Chemistry, Endo, Pathology, HLA and Molecular Biology.

The Company's Bladder Wall Thermo-chemotherapy (BWT) treats NMIBC by combination of chemotherapy instillation with uniform high temperature over the entire bladder lumen by a precisely heated mitomycin (MMC) solution.
The BWT powerful heat-chemotherapy synergy is effective with excellent patients' tolerance and clinical outcomes.
Clinical results of BWT in a very difficult group of NMIBC patients already showed about six-times extended disease-free interval following BWT vs. baseline with failed BCG and MMC instillations alone.
More than 9,500 BWT procedures have been performed successfully with very good results.
Elmedical systems are installed in Israel, Germany, Turkey, Spain, Italy, Czech Republic, Croatia, Colombia and Switzerland (soon in England).
Elmedical performed successful proof of concept procedures in overactive bladder (OAB) and interstitial cystitis (IC) and started a formal clinical trial in these two diseases.

Headquartered in Switzerland, Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group active in global markets.
The company identifies, develops and markets innovative products in the areas
of reproductive health, urology, gastroenterology, endocrinology and
orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries
and markets its products in 110 countries. To learn more about Ferring or its
products please visit

GenomeDx Biosciences

GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic oncology that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is based in Vancouver, British Columbia and San Diego, California.
Learn more at

Getter Group Ltd
Bio-Med Division
7, Shimshom Road
Petach-Tikva 4912502

Getter is active in a few fields with Urology products
COOK Medical Urology leading company, produce high quality products, leading the Israeli market. Urethral Stents, Dilation access and balloons, Stone extractors, Wire Guides and Catheters.
AMS has been a leading innovator in the field of erectile restoration for over three decades. Today we offer the broadest line of penile implant options in the industry.
Also is the leading innovator in developing minimally invasive treatment options for enlarged prostate or BPH (benign prostatic hyperplasia). We help physicians cover the complete spectrum of solutions for patients suffering from enlarged prostate, from mildly symptomatic to severely obstructed.
Male Sling
New outpatient technology for men suffering from mild stress urinary incontinence
Urinary Prosthesis is an implanted device designed to allow patients who have incontinence (loss of urinary control) due to prostate surgery to control urination.

GSK Israel, 25 Basel St.
Petach Tikva, 4900202, Israel
Tel: 03-9297100

GSK is a science-led global healthcare company. GSK researchers and develops a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. GSK also has a significant global presence with commercial operations in more than 150 countries, a network of 84 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China. GSK wants to help people to do more, feel better, live longer.

39 Alexander Yanai St.
Petach Tikva 4927735, Israel

Isotopia Molecular Imaging Ltd. was incorporated in 2006 to provide radioactive isotopes to the growing sector of nuclear medicine in Israel. The vision of Isotopia is to become the leader in the field of molecular imaging and radiotherapy.
Our Nuclear pharmacy is approved to manufacture, import and distribute both SPECT and PET isotopes and operates under strict Quality Control Procedures QCP using highly advanced technologies and equipment.
The team includes well trained and experienced nuclear engineers, laboratory technicians, cyclotron operators, QA, Nuclear Pharmacists, R&D, physicists and chemists.
Isotopia operates a PETtrace GE Healthcare Cyclotron and is installing a second cyclotron with collaboration with Rambam medical center.
In 2015, Isotopia has introduced to the Israeli market Ga68 PSMA for precise diagnosis of PC and improved therapy planning. Since then working to incorporate the Lu177 PSMA targeted treatment together creating a THERANOSTICTS approach that is growing rapidly worldwide as therapeutic regimes increasingly being integrated and guided by diagnostic practices such as medical imaging.

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: Oncology, Hemato-Oncology, Infectious Diseases, Mental Health (Bipolar I Disorder, Schizophrenia), and Attention Deficit Hyperactivity Disorder (ADHD)
Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals.
Janssen is named after Dr. Paul Janssen, a leading Belgian researcher, pharmacologist, and general practitioner. Dr. Janssen led a group of researchers to discover a medicine that helped change the way mental health patients were treated. His company, Janssen Pharmaceutical, joined the Johnson & Johnson family of companies in 1961. Our company remains guided by Dr. Janssen's values of excellence and innovation.   

Medison is Israel's leading international pharmaceutical group for innovative niche healthcare solutions.
With three generations of experience Medison specializes in Oncology, Hematology and Rare Genetic Disease representing companies such as Shire, Ipsen, Amgen, GenomeDX and more.
With products like Decipher, a genomic test that informs decisions about the course of treatment for men after prostate surgery and XGEVA for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

With over 20 years of experience and expertise in shockwave therapy solutions, Medispec continuously introduces competitive systems and technological breakthroughs to the market. The company specializes in shockwave-based systems for urology, cardiovascular and orthopedics applications. Medispec services clinics, medical centers and hospitals in over 80 countries worldwide. All of the company's systems offer modular design, versatility, ease of use and high degree of mobility, for delivering innovative technology in a fast and efficient manner. All Medispec products comply with FDA* and CE regulations.

(Meditec) is a family owned pharmaceutical manufacturer engaged and specialized in development, production, distribution and marketing of pharmaceuticals (Rx and OTC), special nutritional supplements and medical devices.
Sam-On (Meditec) is a fully integrated company possessing active R&D
manufacturing, registration and regulatory affairs, marketing, sales and nationwide distribution capabilities, in house.
Our products are market leaders in their therapeutic categories and have driven growth of the company every year.
Sam-On (Meditec) specializes in developing and manufacturing OTC drugs containing unique formulations/combinations with an added medical value (including natural or herbal ingredients).
Sam-On (Meditec)'s portfolio includes broad therapeutic categories such as cardiovascular, gastroenterology, urology, gynecology and women's health, respiratory, diabetes and CNS disorders.

At Novartis Oncology, our mission is to help improve the lives of cancer patients. We are passionate about the discovery and development of innovative medicines that transform the way people live with cancer and rare diseases. We seek to provide a wide range of innovative therapies to help meet unmet medical needs, as well as practical solutions to advance the care of patients.
Novartis Oncology offers an unmatched portfolio of 22 oncology, hematology and rare disease medicines to treat more than 25 conditions worldwide. New therapies acquired from the GSK oncology portfolio in melanoma, renal cell carcinoma and hematology complement Novartis Oncology's existing group of practice-changing medicines to create one of the largest portfolios of drugs in oncology and hematology targeting important biological disease pathways.

Pfizer Pharmaceuticals Israel Ltd.
9 Shenkar St., Herzeliya Pituach, 46725, P.O.Box 12133
Tel: 972-9-9700500 Fax: 972-9-9700501

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.
Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products.
Consistent with our responsibility as the world's leading Biopharmaceutical Company, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).

Sela medical Ltd. was founded in 2001 with the intention of implementing all the obtained knowledge and professionalism of its team. Sela Medical is a solid and well established distributor within the Israeli market.
Our mission is to deliver premier healthcare products for doctors and patients. We are dedicated to an absolute customers satisfaction and to building a long-term service-oriented relationship with our clients.
We take pride in our carefully chosen product portfolio, uncompromised professionalism and excellent customer service at all levels of the company.
Our company is considered one of the fastest developing medical distributors in the Israeli market.

STEBA Biotech is a privately owned biotechnology company headquartered in Luxembourg with offices in France, Israel, Switzerland, and the US.
Steba Biotech's flagship product, TOOKAD®, for treatment of prostate cancer, is a first-in-class photosensitizer derived from palladium-substituted bacteriochlorophyll and developed in collaboration with the Weizmann Institute. It was designed to address limitations of previous attempts in photodynamic therapies. Through its high solubility and activation with low energy, near-infrared light, TOOKAD® enables highly localized vascular occlusion that triggers targeted necrosis of tumor lesions, while sparing surrounding healthy tissue.
Based on positive results from Phase 3 clinical trials in Europe and Latin America STEBA Biotech has received, marketing authorization for TOOKAD® from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the Mexican health authority. Approval for treatment with TOOKAD® has also been granted in April 2016 by the Israeli Ministry of Health under Tofes 29 gimmel and in May was submitted for marketing authorization. TOOKAD® has also been submitted for marketing authorization to the EMA and other Latin American countries.
STEBA Biotech is also pursuing early stage studies Phase I/IIa of TOOKAD® in other solid tumors (esophageal cancer, urothelial carcinoma, advanced prostate cancer, renal carcinoma, and triple negative breast cancer) in collaboration with Memorial Sloan Kettering Cancer Center, the Weizmann Institute, and Oxford University.

MEL Medical Enterprises Ltd.
6 Odem, POB 7166 Kiryat Matalon
Petah Tikva, 49170 Israel
Mob: +972-54-456 65 92
Tel: +972 3 924 48 30
Fax: +972 3 92453 40

Medical Enterprises Group develops innovative minimally invasive technologies providing benefits for both patients and the healthcare systems. The lead product, Synergo® RITE (RF induced thermo-chemotherapy effect) offers clinically effective, safe and easy way to deliver deep tissue hyperthermia with Chemotherapeutic instillation for NMIBC. Synergo® has become a common practice worldwide and provides urologists with an effective tool to treat intermediate and high-risk patients who failed previous treatments or have no other available alternatives. Synergo® treatment reduces recurrences and the need for repetitive surgical interventions thus reducing the frequency of treatment and reducing the necessity for cystectomy, radiotherapy and/or expensive systemic treatment.Thousands of patients were treated successfully and over 30 scientific publications including RCTs were published, proving its long-term safety and efficacy.

Tec-O-Pharm-Libra Ltd.
P.O. Box 45054, Jerusalem 91450 Israel
Tel: 972-2-5870875; Fax: 972-2-5870873; E-mail:;

Tec-O-Pharm Group is a private enterprise, founded in 1992 and based in Jerusalem.
We are dedicated to providing our international partners the full range of professional services in the fields of Urology, Pain management, Anesthesia, Oncology and Women`s health.
Our leading brands Spasmex 30 and Spasmex 15 (Trospium), are the safest treatment for urinary incontinence, being the only anticholinergic molecule that is not metabolized via CYP-450 in the liver, thus avoiding drug-drug interactions, and with low probability of passing the blood brain barrier, avoiding cognitive disorders associated with other anticholinergics. Spasmex is presented in tablets of 30 mg and 15 mg, allowing maximum flexibility for the needs of the patient.

Teva, a global power in generic and specialty medicines, delivers high-quality, patient-centric healthcare solutions to 200 million people around the world every day.
Founded in Jerusalem 115 years ago, Teva employs 43,000 workers in 60 countries.
Teva is the world's largest maker of generic medicines, and owns the largest drug cabinet in the world, spanning nearly every therapeutic area.
It is a world leader in innovative specialty pharmaceuticals, with prominent portfolios in Respiratory and Central Nervous System, including multiple sclerosis, pain, migraine, movement disorders and neurodegenerative diseases.
Through its comprehensive and accessible product offerings, Teva contributes immense savings to healthcare systems globally.

Oncotest-Teva is a pioneer in the field of personalized medicine in Israel.
For almost two decades, Oncotest-Teva has been focusing on identification of novel approaches to diagnosing malignant diseases and predicting the course of disease, according to the unique genetic profile of the patient and tumor cells, and more precise and more effective matching of therapeutic directions.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.


UroGen Pharma (formerly TheraCoat) is a clinical stage biotechnology company with the goal of transforming local therapy for urological pathologies. The Company is focusing on the development of novel pharmaceutical solutions for several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer, carcinoma in-situ (CIS) bladder cancer and low-grade upper tract urothelial carcinoma (UTUC), an unmet medical need for which there are no FDA approved drugs. UroGen's drug candidates may have the potential to replace the burdensome and costly surgical interventions and shift the use of local drug treatment from adjuvant to first line therapy.